Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

OTHER 10 NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 15 CNS 10 Gastrointestinal 8 Thoracic 6 Genitourinary 4 Dermatologic 3 Head & Neck 2 Tumor-Agnostic 1 NET 1 Gynecologic 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Everolimus 23 pasireotide 14 lutetium Lu 177 dotatate 10 Octreotide 10 lanreotide 9 surufatinib 8 Carboplatin 8 Paclitaxel 7 pembrolizumab 5 amino-acid, glucose, and electrolyte solution 5 Thyrotropin Alfa 5 Sunitinib 5 Nivolumab 5 Injections 5 3-Iodobenzylguanidine 5 relacorilant 4 fosbretabulin 4 Temozolomide 4 Fulvestrant 4 Etoposide 4 Data Collection 4 Cisplatin 4 vandetanib 3 selpercatinib 3 dabrafenib 3 anlotinib 3 Mifepristone 3 Lutetium-177 3 Lutetium 3 Irinotecan 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Surgical Procedures, Operative × Endocrine × Clear all

NCT03012789 2024-04-30

NETest_Sx

Wren Laboratories LLC

Phase NA Active not recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡